Vène et al. CPB- and GBVA-derived peptides trigger efficient cell internalization of bioconjugates and functionalized PMLABe-based nanoparticles in human hepatoma cells

Published: 6 April 2022| Version 1 | DOI: 10.17632/tcx26rtxf8.1
Pascal Loyer


In order to identify peptides selected from the literature that exhibit the strongest tropism towards human hepatoma cells, cell uptake assays were performed using biotinylated synthetic peptides bound to fluorescent streptavidin or engrafted onto nanoparticles (NPs) prepared from biotin-poly(ethylene glycol)-block-poly(benzyl malate) (Biot-PEG-b-PMLABe) via streptavidin bridging. Two peptides derived from the circumsporozoite protein of Plasmodium berghei- (CPB) and George Baker (GB) Virus A (GBVA10-9) strongly enhanced the endocytosis of both streptav-idin conjugates and NPs in hepatoma cells compared to primary human hepatocytes and non-hepatic cells. Unexpectedly, the uptake of CPB- and GBVA10-9 functionalized PEG-b-PMLABe-based NPs by hepatoma cells involved, at least in part, the peptide binding to apolipoproteins, which would promote NP’s interactions with cell membrane receptors of HDL particles. In addition, CPB and GBVA10-9 peptide-streptavidin conjugates favored the uptake by hepatoma cells over that of human macrophages, known to strongly internalize nanoparticles by phagocytosis. These two peptides are promising candidate ligands for targeting hepatocellular carcinomas.





Conjugate, Hepatocellular Carcinoma, Cancer Peptide, Nanoparticle as Delivery Vehicle